论文部分内容阅读
目的:探讨奥沙利铂联合胸腺肽在肺癌合并恶性胸腔积液治疗中的临床疗效。方法:将2014年1月~2016年12月在我院进行治疗的76例肺癌合并恶性胸腔积液患者作为研究对象,并将其按照随机数字法分成观察组38例与对照组38例,观察组患者在常规对症治疗的基础上给予奥沙利铂联合胸腺肽治疗,对照组患者在常规对症治疗的基础上给予单一的奥沙利铂治疗,分别对两组患者的临床治疗效果、T淋巴细胞指标、炎症因子水平及不良反应情况进行统计对比。结果:观察组患者的临床治疗效果明显好于对照组,观察组患者的T淋巴细胞指标明显高于对照组,观察组患者的炎症因子水平明显低于对照组,观察组患者的不良反应发生率明显低于对照组。结论:奥沙利铂联合胸腺肽在肺癌合并恶性胸腔积液治疗中的临床效果显著,与单一奥沙利铂比较具有更好的疗效、更高的安全性,有效提高了患者的生存质量,值得临床的推广及应用。
Objective: To investigate the clinical efficacy of oxaliplatin combined with thymosin in the treatment of lung cancer complicated with malignant pleural effusion. Methods: From January 2014 to December 2016 in our hospital, 76 patients with malignant pleural effusion in patients with lung cancer were enrolled and divided into observation group (38 cases) and control group (38 cases) according to random number method. The patients were given oxaliplatin combined with thymosin on the basis of routine symptomatic treatment. Patients in the control group were given a single oxaliplatin treatment on the basis of conventional symptomatic treatment. The clinical efficacy, T lymphocyte Indicators, levels of inflammatory cytokines and adverse reactions for statistical comparison. Results: The clinical effect of the observation group was significantly better than that of the control group. The T lymphocyte index of the observation group was significantly higher than that of the control group. The inflammatory factor level of the observation group was significantly lower than that of the control group. The incidence of adverse reactions in the observation group Obviously lower than the control group. Conclusion: The clinical efficacy of oxaliplatin combined with thymosin in the treatment of patients with lung cancer complicated with malignant pleural effusion is significant. Compared with single oxaliplatin, the combination of oxaliplatin and thymosin has better curative effect, higher safety and effectively improves the quality of life of patients. Clinical promotion and application.